New York, Feb 6, 2026, 17:39 EST — Trading after the bell.
- Obesity-drug stocks are moving again, with FDA decisions on compounded GLP-1s taking center stage.
- Eli Lilly is making this change following a rocky period fueled by issues around cash-pay pricing and rival copycat supply.
- Traders are looking ahead to next week, eyeing the specifics on enforcement and tracking just how rapidly pricing pressure might ripple through.
Eli Lilly jumped 3.7% to $1,058.18 in late trading Friday after U.S. regulators moved to clamp down on GLP-1 ingredients in unapproved compounded drugs. The Department of Health and Human Services’ general counsel also referred Hims & Hers, a telehealth firm, to the Justice Department for investigation; Hims tumbled almost 12% postmarket.
Compounded weight-loss pills are at the center of a fierce contest that’s now shifting the outlook for branded GLP-1 drugs, including Lilly’s Zepbound and Mounjaro. GLP-1, a gut hormone that diabetes and obesity drugs act on, has helped power gains in major pharma shares this past year.
Hims is shaking things up with its move to offer a $49 compounded take on Novo Nordisk’s Wegovy pill, pushing investors to weigh risks around patents, legal exposure, and how fast prices could fall. “Until this issue is resolved, it adds another level of uncertainty,” Union Investment’s Markus Manns said. Reuters
TD Cowen’s Michael Nedelcovych sums up the current landscape: “a compounder can create a copycat version” just by making a tweak and claiming it helps patients. It’s a critical point for branded drugmakers, now doubling down on direct-to-consumer sales—where buyers pay their own bills, and there’s barely any room on price. Reuters
Lilly shares dropped the day before, with the sector reacting to FDA Commissioner Marty Makary’s warning that regulators planned to “take swift action” on illegal copycat drugs. A Lilly spokesperson dismissed the products as “untested knockoffs.” But Bernstein’s Christian Moore wasn’t expecting a speedy response from U.S. officials. Reuters
Beyond the obesity space, CVS Health’s Caremark unit is cutting Eli Lilly’s osteoporosis drug Forteo from certain preferred formularies in favor of lower-cost generics, effective April 1. Caremark is also set to include biosimilar versions of Amgen’s Prolia, underscoring just how quickly pricing dynamics can shift after cheaper competition lands.
Still, enforcement often trails the news cycle, and compounding operates in this ambiguous space between federal and state scrutiny. Should those lower-cost alternatives continue to flood the market — or if brand-name producers speed up their discounting to protect their cash-pay turf — any bounce in the sector might vanish as quickly as it arrived.
Lilly wants investors looking ahead: it’s projecting 2026 earnings at $33.50 to $35 a share, with revenue between $80 billion and $83 billion, following a strong fourth quarter driven by Mounjaro and Zepbound. “Price will be a drag in the low- to mid-teens,” Chief Financial Officer Lucas Montarce warned. The next big event? The FDA’s expected April decision on orforglipron, Lilly’s experimental oral weight-loss drug. Reuters
